Sort   by:  
 Page size 

Metabolic reprogramming is critical for tumor initiation and progression. However, the exact impact of specific metabolic changes on cancer progression is poorly understood. Here, we integrate multimodal analyses of primary and metastatic clonally-related clear cell renal cancer cells (ccRCC) gro...

2022-12-08 | MTBLS5615 | MetaboLights
A protocol for harvesting and extracting extracellular metabolites from an in vitro model of human renal cell lines was developed to profile the exometabolome by means of a discovery-based metabolomics approach using ultraperformance liquid chromatography coupled to quadrupole-time-of-flight mass sp...
2018-11-14 | MTBLS737 | MetaboLights

International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), fo...

2024-03-26 | MTBLS9394 | MetaboLights

The ultimate goal of surgical treatment in cancer is to remove the tumor mass for restoring a healthy state. A 16-lipid panel that discriminated healthy controls from clear cell renal cell carcinoma (ccRCC) patients in a prior study was evaluated in the present work in paired-serum samples collec...

2023-01-02 | MTBLS3838 | MetaboLights

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy. Yet, no rapid, non-invasive biomarkers are available for diagnosis or screening. Urine represents an ideal analyte matrix due to its accessibility, low invasiveness, longitudinal sampling and the kidney’s central role i...

2026-08-16 | MTBLS12025 | MetaboLights
In order to clarify the molecular mechanism involved in renal carcinogenesis, and identify molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 15 surgical specimens of clear cell renal cell carcinoma (RCC), compared to normal renal cortex, using a combi...
ORGANISM(S): Homo sapiens 

Metabolic reprogramming is a defining feature of cancer; however, how it contributes to therapeutic resistance remains incompletely understood. Here we show that loss of aldo-ketoreductase 1A1 (AKR1A1) in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) disrupts terminal glycolytic f...

2026-07-10 | MTBLS15003 | MetaboLights
This study investigated metabolic alterations associated with fumarate hydratase (FH) deficiency in clear cell renal cell carcinoma (ccRCC). Targeted metabolomic analysis was performed in 786-O and RCC4 cells with or without FH knockdown, using three biological replicates per condition. Intracellula...
2026-10-16 | MTBLS15359 | MetaboLights

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy. Yet, no rapid, non-invasive biomarkers are available for diagnosis or screening. Urine represents an ideal analyte matrix due to its accessibility, low invasiveness, longitudinal sampling and the kidney’s central role i...

2026-07-15 | MTBLS14671 | MetaboLights

A discovery-based lipid profiling study of serum samples from a cohort that included patients with clear cell Renal Cell Carcinoma (ccRCC) stage I, II, III, and IV (n=112) and controls (n=52) was performed using ultraperformance liquid chromatography coupled to quadrupole-time-of-flight mass spec...

2020-11-20 | MTBLS1839 | MetaboLights
Sort   by:  
 Page size